MX2022006633A - Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant. - Google Patents
Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant.Info
- Publication number
- MX2022006633A MX2022006633A MX2022006633A MX2022006633A MX2022006633A MX 2022006633 A MX2022006633 A MX 2022006633A MX 2022006633 A MX2022006633 A MX 2022006633A MX 2022006633 A MX2022006633 A MX 2022006633A MX 2022006633 A MX2022006633 A MX 2022006633A
- Authority
- MX
- Mexico
- Prior art keywords
- antipsychotic
- gain
- weight gain
- grm
- methods
- Prior art date
Links
- 230000004584 weight gain Effects 0.000 title abstract 5
- 235000019786 weight gain Nutrition 0.000 title abstract 5
- 230000000561 anti-psychotic effect Effects 0.000 title abstract 3
- GVVUZBSCYAVFTI-IYARVYRRSA-N miricorilant Chemical compound FC(F)(F)C1=CC=CC(CC2=C(NC(=O)NC2=O)[C@H]2CC[C@@H](CC2)C2=CC=CC=C2)=C1 GVVUZBSCYAVFTI-IYARVYRRSA-N 0.000 title abstract 3
- 229940121462 miricorilant Drugs 0.000 title abstract 3
- 229940117965 Glucocorticoid receptor modulator Drugs 0.000 abstract 5
- 229940124604 anti-psychotic medication Drugs 0.000 abstract 5
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- YJDDXMSIMBMMGY-UHFFFAOYSA-N 2-cyclohexylpyrimidine Chemical compound C1CCCCC1C1=NC=CC=N1 YJDDXMSIMBMMGY-UHFFFAOYSA-N 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 abstract 1
- 108090000790 Enzymes Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 230000036765 blood level Effects 0.000 abstract 1
- 229960004170 clozapine Drugs 0.000 abstract 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960005017 olanzapine Drugs 0.000 abstract 1
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 abstract 1
- 229960001534 risperidone Drugs 0.000 abstract 1
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 abstract 1
- 150000003626 triacylglycerols Chemical class 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen métodos y composiciones para tratar a un sujeto en riesgo de, o que sufre de aumento de peso inducido por antipsicóticos. Los métodos incluyen la administración de un modulador del receptor de glucocorticoides (GRM) de ciclohexil pirimidina tal como miricorilant (CORT118335) a un paciente que recibe, ha recibido o se espera que reciba un fármaco antipsicótico como olanzapina, risperidona, clozapina u otro medicamento antipsicótico inductor de peso. El GRM (por ejemplo, miricorilant) puede administrarse por vía oral. La administración de tal GRM junto con la medicación antipsicótica puede reducir la cantidad de peso, o reducir la tasa de aumento de peso, o prevenir el aumento de peso, que de otro modo se debería a la medicación antipsicótica sola. Los métodos pueden revertir el aumento de peso en un paciente al que se le administró previamente medicación antipsicótica. La administración de tal GRM con medicación antipsicótica puede reducir, o evitar el aumento, o prevenir el aumento, o revertir el aumento de la resistencia a la insulina o de los niveles sanguíneos de las enzimas hepáticas (AST, ALT), los triglicéridos o la insulina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962946957P | 2019-12-11 | 2019-12-11 | |
| PCT/US2020/064520 WO2021119432A1 (en) | 2019-12-11 | 2020-12-11 | Methods of treating antipsychotic-induced weight gain with miricorilant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006633A true MX2022006633A (es) | 2022-06-24 |
Family
ID=76316599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006633A MX2022006633A (es) | 2019-12-11 | 2020-12-11 | Metodos de tratamiento del aumento de peso inducido por antipsicoticos con miricorilant. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11903945B2 (es) |
| EP (1) | EP4072556A4 (es) |
| JP (1) | JP7569492B2 (es) |
| KR (1) | KR20220113767A (es) |
| CN (1) | CN114929229A (es) |
| AU (1) | AU2020400061A1 (es) |
| CA (1) | CA3158745A1 (es) |
| CL (1) | CL2022001250A1 (es) |
| IL (1) | IL291775A (es) |
| MX (1) | MX2022006633A (es) |
| UA (1) | UA128573C2 (es) |
| WO (1) | WO2021119432A1 (es) |
| ZA (1) | ZA202203668B (es) |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS322220B1 (es) | 1954-11-30 | 1957-04-11 | ||
| DE3011809A1 (de) | 1980-03-27 | 1981-10-01 | Cassella Ag, 6000 Frankfurt | Pyrimidyl-chinazoline, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische praeparate und ihre verwendung |
| IL72729A (en) | 1983-09-26 | 1988-02-29 | Lilly Co Eli | Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them |
| JPS6417555A (en) | 1987-07-13 | 1989-01-20 | Tokyo Electric Co Ltd | Facsimile |
| US5008267A (en) | 1988-10-29 | 1991-04-16 | Mitsui Toatsu Chemicals, Incorporated | Pyrimidinedione compounds, method of producing the same and antiarrythmic agents containing the same |
| GB8828669D0 (en) | 1988-12-08 | 1989-01-11 | Lilly Industries Ltd | Organic compounds |
| JP3160941B2 (ja) | 1991-06-17 | 2001-04-25 | 東レ株式会社 | カルバゾール誘導体および免疫抑制剤 |
| JPH06128238A (ja) | 1992-10-20 | 1994-05-10 | Mitsui Toatsu Chem Inc | 新規ピリミジンジオン誘導体 |
| FR2697252B1 (fr) | 1992-10-28 | 1994-12-09 | Fournier Ind & Sante | Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique. |
| WO1995004734A1 (en) | 1993-08-06 | 1995-02-16 | Smithkline Beecham Farmaceutici S.P.A. | Hydroisoquinoline derivatives |
| EP0722732A1 (en) | 1995-01-24 | 1996-07-24 | Mitsui Toatsu Chemicals, Inc. | Long-acting drug formulation containing pyrimidinedione derivatives |
| WO1998027986A1 (en) | 1996-12-24 | 1998-07-02 | Zymogenetics, Inc. | Treatment agents and methods for treating type ii diabetes and symptoms of type ii diabetes |
| IL135469A0 (en) | 1997-10-06 | 2001-05-20 | Univ Leland Stanford Junior | Methods for treating psychosis associated with glucocorticoid related dysfunction |
| JP4498602B2 (ja) | 1998-03-10 | 2010-07-07 | リサーチ・トライアングル・インスティチュート | 新規なオピエート化合物、その調製法及び使用法 |
| JP2003505336A (ja) | 1998-05-15 | 2003-02-12 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 痴呆の処置のためのグルココルチコイドレセプターアンタゴニスト |
| GB9911053D0 (en) | 1999-05-12 | 1999-07-14 | Pharmacia & Upjohn Spa | 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents |
| ES2246292T3 (es) | 2000-10-30 | 2006-02-16 | Pfizer Products Inc. | Moduladores de receptor glucocorticoide. |
| GB0029100D0 (en) | 2000-11-29 | 2001-01-10 | Karobio Ab | Compounds active at the glucocorticoid receptor |
| WO2003015692A2 (en) | 2001-07-17 | 2003-02-27 | Smithkline Beecham Corporation | Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same |
| US6680310B2 (en) | 2001-07-23 | 2004-01-20 | Corcept Therapeutics, Inc. | Methods for preventing antipsychotic-induced weight gain |
| US6831093B2 (en) | 2002-01-22 | 2004-12-14 | The Regents Of The University Of California | Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof |
| WO2003084936A2 (en) | 2002-04-10 | 2003-10-16 | Orchid Chemicals & Pharmaceuticals Limited | Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological |
| TW200503994A (en) | 2003-01-24 | 2005-02-01 | Novartis Ag | Organic compounds |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| TWI327915B (en) * | 2003-06-12 | 2010-08-01 | Organon Nv | Pharmaceutical composition comprising antipsychotic agent and use of the antipsychotic agent for treating patients with overweight |
| MXPA06002123A (es) | 2003-09-03 | 2006-05-17 | Wyeth Corp | 42-ester de rapamicina amorfo con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico y composiciones farmaceuticas que los contienen. |
| NZ548374A (en) | 2004-01-09 | 2010-05-28 | Corcept Therapeutics Inc | Azadecalin glucocorticoid receptor modulators |
| NZ550362A (en) | 2004-03-09 | 2010-06-25 | Corcept Therapeutics Inc | Fused ring azadecalin glucocorticoid receptor modulators |
| NZ552984A (en) | 2004-07-02 | 2010-06-25 | Corcept Therapeutics Inc | Modified pyrimidine glucocorticoid receptor modulators |
| PT1928840E (pt) | 2005-04-05 | 2011-10-03 | Hoffmann La Roche | 1h-pirazole-4-carboxamidas, a sua preparação e a sua utilização a título de inibidores de 11-betahidroxiesteróide desidrogenase |
| US7790745B2 (en) | 2005-10-21 | 2010-09-07 | Bristol-Myers Squibb Company | Tetrahydroisoquinoline LXR Modulators |
| CN1965840A (zh) * | 2005-11-18 | 2007-05-23 | 科塞普特治疗公司 | 预防由抗精神病药物引起的体重增加的方法 |
| US7640389B2 (en) | 2006-02-28 | 2009-12-29 | Freescale Semiconductor, Inc. | Non-volatile memory having a multiple block erase mode and method therefor |
| JP2011503081A (ja) | 2007-11-01 | 2011-01-27 | ブリストル−マイヤーズ スクイブ カンパニー | グルココルチコイド受容体、ＡＰ−１および／またはＮＦ−κＢ活性の調節剤として有用な非ステロイド性化合物、並びにその使用 |
| CA2622696A1 (en) * | 2007-11-05 | 2009-05-05 | Diane Mcintosh | Methods and compositions for retarding weight gain associated with use of atypical antipsychotic drugs |
| CN102421437B (zh) | 2009-05-12 | 2014-03-19 | 科赛普特治疗公司 | 固体形式和制备方法 |
| US8710035B2 (en) | 2010-03-24 | 2014-04-29 | The University Of Chicago | Methods and compositions related to glucocorticoid receptor antagonists and breast cancer |
| BR112013004322A2 (pt) | 2010-08-27 | 2016-06-21 | Corcept Therapeutics Inc | moduladores de azadecalin fundidos com piridil-aminas |
| AU2012204232A1 (en) | 2011-01-07 | 2013-06-27 | Corcept Therapeutics, Inc. | Combination steroid and glucocorticoid receptor antagonist therapy |
| CA2830411C (en) * | 2011-03-18 | 2019-05-28 | Corcept Therapeutics, Inc. | Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| ES2767956T3 (es) | 2011-11-11 | 2020-06-19 | Gilead Apollo Llc | Inhibidores de ACC y sus utilizaciones |
| US20130225633A1 (en) | 2012-02-27 | 2013-08-29 | Corcept Therapeutics, Inc. | Phenyl heterocycloalkyl glucocorticoid receptor modulators |
| MY172739A (en) | 2012-05-25 | 2019-12-11 | Corcept Therapeutics Inc | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PT2861611T (pt) | 2012-05-25 | 2016-10-11 | Janssen Sciences Ireland Uc | Nucleósidos de espirooxetano de uracilo |
| US8859774B2 (en) | 2012-05-25 | 2014-10-14 | Corcept Therapeutics, Inc. | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators |
| PT3848027T (pt) | 2013-11-25 | 2023-05-11 | Corcept Therapeutics Inc | Moduladores de recetores de glicocorticoides de azadecalina fundidas com octa-hidro |
| US9943505B2 (en) | 2016-09-09 | 2018-04-17 | Corcept Therapeutics, Inc. | Glucocorticoid receptor modulators to treat pancreatic cancer |
-
2020
- 2020-12-11 WO PCT/US2020/064520 patent/WO2021119432A1/en unknown
- 2020-12-11 IL IL291775A patent/IL291775A/en unknown
- 2020-12-11 EP EP20900160.1A patent/EP4072556A4/en active Pending
- 2020-12-11 US US17/119,582 patent/US11903945B2/en active Active
- 2020-12-11 JP JP2022528536A patent/JP7569492B2/ja active Active
- 2020-12-11 KR KR1020227023596A patent/KR20220113767A/ko unknown
- 2020-12-11 UA UAA202202378A patent/UA128573C2/uk unknown
- 2020-12-11 AU AU2020400061A patent/AU2020400061A1/en active Pending
- 2020-12-11 CA CA3158745A patent/CA3158745A1/en active Pending
- 2020-12-11 MX MX2022006633A patent/MX2022006633A/es unknown
- 2020-12-11 CN CN202080086165.9A patent/CN114929229A/zh active Pending
-
2022
- 2022-03-30 ZA ZA2022/03668A patent/ZA202203668B/en unknown
- 2022-05-12 CL CL2022001250A patent/CL2022001250A1/es unknown
-
2024
- 2024-01-12 US US18/412,258 patent/US20240261287A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20240261287A1 (en) | 2024-08-08 |
| WO2021119432A1 (en) | 2021-06-17 |
| US20210177848A1 (en) | 2021-06-17 |
| CA3158745A1 (en) | 2021-06-17 |
| KR20220113767A (ko) | 2022-08-16 |
| UA128573C2 (uk) | 2024-08-14 |
| CL2022001250A1 (es) | 2023-02-10 |
| EP4072556A1 (en) | 2022-10-19 |
| JP7569492B2 (ja) | 2024-10-18 |
| CN114929229A (zh) | 2022-08-19 |
| ZA202203668B (en) | 2024-09-25 |
| AU2020400061A1 (en) | 2022-04-14 |
| US11903945B2 (en) | 2024-02-20 |
| IL291775A (en) | 2022-06-01 |
| JP2023505948A (ja) | 2023-02-14 |
| EP4072556A4 (en) | 2024-01-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pandina et al. | A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia | |
| PH12015501009A1 (en) | A composition for treating diabetes or diabesity comprising oxyntomodulin analog | |
| TN2016000500A1 (en) | Composition for Treating Diabetes Comprising Long-acting lnsulin Analogue Conjugale and Long-acting lnsulinotropic Peptide Conjugale | |
| EP2216024A3 (en) | Use of Ranolazine for the treatment of cardiovascular diseases | |
| NZ608292A (en) | Use of lysosomal acid lipase for treating lysosomal acid lipase deficiency in patients | |
| Hindmarsh | The child with difficult to control C ongenital A drenal H yperplasia: is there a place for continuous subcutaneous hydrocortisone therapy | |
| Alten et al. | Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approaches | |
| WO2012154587A3 (en) | Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents | |
| EA201070557A1 (ru) | Способы и композиции для замедления набора веса, связанного с применением атипичных антипсихотических препаратов | |
| ZA202203668B (en) | Methods of treating antipsychotic-induced weight gain with miricorilant | |
| JP2020536854A5 (es) | ||
| Cheng et al. | Management of imatinib‐related exacerbation of psoriasis in a patient with a gastrointestinal stromal tumour | |
| Grover et al. | Augmentation of clozapine with ECT: observations from India | |
| Ju et al. | Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety | |
| BR112022006748A2 (pt) | Métodos para tratar um indivíduo que sofre de ganho de peso e em risco de sofrer ganho de peso induzidos por antipsicótico | |
| MX2022006045A (es) | Metodos de administracion de voxelotor. | |
| WO2006004696A3 (en) | Compositions and methods for the prevention and control of insulin-induced hypoglycemia | |
| Brümmendorf et al. | Second-Line Bosutinib in Patients with Chronic Phase Chronic Myeloid Leukemia (CP CML) Resistant or Intolerant to Prior Imatinib: An 8-Year Update | |
| CN101919844A (zh) | 防治自身免疫性疾病的化合物及其用途 | |
| Jani | Severe lactic acidosis: case report | |
| Sat et al. | The usage of antihyperlipidemic agents in type 2 diabetic patients with hemodialysis in two public centers in Cambodia | |
| Steringer-Mascherbauer et al. | Transitioning From Subcutaneous To Intravenous Treprostinil Administered By The Implantable Infusion Pump LenusPro®: A Single-Center Pilot Study | |
| LI et al. | Glutamine up-regulates GLP-1 expression in colon tissue of type 2 diabetic rats | |
| Jung | Scientific journey of linagliptin, a DPP-4inhibitor, over 5years | |
| Jung | Acute pancreatitis: case report |